Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 1
2003 1
2004 2
2005 1
2006 6
2007 1
2008 4
2009 4
2010 3
2011 4
2012 6
2013 11
2014 10
2015 12
2016 11
2017 7
2018 8
2019 4
2020 9
2021 14
2022 11
2023 7
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Whole-genome characterization of chemoresistant ovarian cancer.
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group; Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD. Patch AM, et al. Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410. Nature. 2015. PMID: 26017449
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Tam CS, et al. Among authors: lade s. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519. N Engl J Med. 2018. PMID: 29590547 Free article. Clinical Trial.
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Minson A, Hamad N, Cheah CY, Tam C, Blombery P, Westerman D, Ritchie D, Morgan H, Holzwart N, Lade S, Anderson MA, Khot A, Seymour JF, Robertson M, Caldwell I, Ryland G, Saghebi J, Sabahi Z, Xie J, Koldej R, Dickinson M. Minson A, et al. Among authors: lade s. Blood. 2024 Feb 22;143(8):673-684. doi: 10.1182/blood.2023021306. Blood. 2024. PMID: 37883795 Clinical Trial.
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I; Australian Ovarian Cancer Study Group; Gertig D, DeFazio A, Bowtell DD. Tothill RW, et al. Among authors: lade s. Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196. Clin Cancer Res. 2008. PMID: 18698038
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Handunnetti SM, Anderson MA, Burbury K, Thompson PA, Burke G, Bressel M, Di Iulio J, Hicks RJ, Westerman D, Lade S, Pott C, Agarwal R, Koldej R, Ritchie D, Dreyling M, Dawson MA, Dawson SJ, Seymour JF, Roberts AW, Tam CS. Handunnetti SM, et al. Among authors: lade s. Blood. 2024 Aug 22;144(8):867-872. doi: 10.1182/blood.2023023388. Blood. 2024. PMID: 38662991 Free PMC article. Clinical Trial.
Rare T-Cell Subtypes.
van der Weyden C, McCormack C, Lade S, Johnstone RW, Prince HM. van der Weyden C, et al. Among authors: lade s. Cancer Treat Res. 2019;176:195-224. doi: 10.1007/978-3-319-99716-2_10. Cancer Treat Res. 2019. PMID: 30596220
WTO must ban harmful fisheries subsidies.
Sumaila UR, Skerritt DJ, Schuhbauer A, Villasante S, Cisneros-Montemayor AM, Sinan H, Burnside D, Abdallah PR, Abe K, Addo KA, Adelsheim J, Adewumi IJ, Adeyemo OK, Adger N, Adotey J, Advani S, Afrin Z, Aheto D, Akintola SL, Akpalu W, Alam L, Alava JJ, Allison EH, Amon DJ, Anderies JM, Anderson CM, Andrews E, Angelini R, Anna Z, Antweiler W, Arizi EK, Armitage D, Arthur RI, Asare N, Asche F, Asiedu B, Asuquo F, Badmus L, Bailey M, Ban N, Barbier EB, Barley S, Barnes C, Barrett S, Basurto X, Belhabib D, Bennett E, Bennett NJ, Benzaken D, Blasiak R, Bohorquez JJ, Bordehore C, Bornarel V, Boyd DR, Breitburg D, Brooks C, Brotz L, Campbell D, Cannon S, Cao L, Cardenas Campo JC, Carpenter S, Carpenter G, Carson RT, Carvalho AR, Castrejón M, Caveen AJ, Chabi MN, Chan KMA, Chapin FS, Charles T, Cheung W, Christensen V, Chuku EO, Church T, Clark C, Clarke TM, Cojocaru AL, Copeland B, Crawford B, Crépin AS, Crowder LB, Cury P, Cutting AN, Daily GC, Da-Rocha JM, Das A, de la Puente S, de Zeeuw A, Deikumah SKS, Deith M, Dewitte B, Doubleday N, Duarte CM, Dulvy NK, Eddy T, Efford M, Ehrlich PR, Elsler LG, Fakoya KA, Falaye AE, Fanzo J, Fitzsimmons C, Flaaten O, Florko KRN, Aviles MF, Folke C, F… See abstract for full author list ➔ Sumaila UR, et al. Among authors: lade s. Science. 2021 Oct 29;374(6567):544. doi: 10.1126/science.abm1680. Epub 2021 Oct 28. Science. 2021. PMID: 34709891 No abstract available.
Safe and just Earth system boundaries.
Rockström J, Gupta J, Qin D, Lade SJ, Abrams JF, Andersen LS, Armstrong McKay DI, Bai X, Bala G, Bunn SE, Ciobanu D, DeClerck F, Ebi K, Gifford L, Gordon C, Hasan S, Kanie N, Lenton TM, Loriani S, Liverman DM, Mohamed A, Nakicenovic N, Obura D, Ospina D, Prodani K, Rammelt C, Sakschewski B, Scholtens J, Stewart-Koster B, Tharammal T, van Vuuren D, Verburg PH, Winkelmann R, Zimm C, Bennett EM, Bringezu S, Broadgate W, Green PA, Huang L, Jacobson L, Ndehedehe C, Pedde S, Rocha J, Scheffer M, Schulte-Uebbing L, de Vries W, Xiao C, Xu C, Xu X, Zafra-Calvo N, Zhang X. Rockström J, et al. Among authors: lade sj. Nature. 2023 Jul;619(7968):102-111. doi: 10.1038/s41586-023-06083-8. Epub 2023 May 31. Nature. 2023. PMID: 37258676 Free PMC article.
Defining double-hit lymphoma in the clinic.
Blombery P, Lade S. Blombery P, et al. Among authors: lade s. Blood. 2021 Apr 22;137(16):2132-2133. doi: 10.1182/blood.2020009465. Blood. 2021. PMID: 33885709 Free article. No abstract available.
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K, Krais JJ, Wang Y, Vandenberg CJ, Patel P, Cai KQ, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Betsch R, Xu L, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, McNeish I, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, Swisher EM, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. Nesic K, et al. Mol Cancer. 2024 Aug 5;23(1):158. doi: 10.1186/s12943-024-02048-1. Mol Cancer. 2024. PMID: 39103848 Free PMC article.
123 results